Clinical trial technology firms Suvoda and Greenphire have completed their merger, bringing together platforms focused on trial supply, consent, outcomes data collection, and clinical payments under a single leadership and ownership structure.

The combined company will operate as Suvoda, with Greenphire continuing as a product brand. The merger is intended to create a more integrated offering for sponsors and sites, combining operational and financial technologies on a single platform.

According to the companies, the goal is to simplify trial workflows and improve the experience for sponsors, sites, and patients, while enabling deeper data insights through a unified system.

Jagath Wanninayake, Suvoda’s founder, will serve as CEO of the combined business. Thoma Bravo is the lead strategic investor, alongside minority investors Bain Capital Tech Opportunities and LLR Partners.

“We are thrilled to announce the completion of our merger and the beginning of our new journey together,” said Wanninayake.

“This partnership represents a significant milestone in our mission to optimize the financial and operational aspects of clinical trials. As one firm, we are now better able to deliver for our customers by meeting their evolving needs and providing them with enhanced solutions that will drive efficiency, reduce costs, and ultimately improve patient outcomes.”

Suvoda, founded in 2013, provides randomization and trial supply management (RTSM), eConsent, and patient outcomes tools. Greenphire, founded in 2008, offers global payment and financial lifecycle management solutions for clinical trials, including patient reimbursements and site payments.

Together, the companies support thousands of trials globally, with Greenphire reportedly supporting more than one million active trial participants across 80 countries.

The companies say this consolidation reflects growing demand for unified systems in clinical operations, as sponsors seek to streamline trial execution and enhance patient and site engagement.